Tirzepatid: the key facts about tirzepatide before you decide

Which decision are you actually making here?

Most people searching for tirzepatide are trying to answer one of three questions: does it work well enough to be worth it, am I likely to qualify, and what does getting it actually involve? Those are the right questions, and they are worth separating. The medicine's track record, your individual eligibility, and the access route are three distinct things — conflating them leads people to either dismiss treatment prematurely or assume approval before a clinician has assessed them.

Tirzepatide is sold in the UK under the brand name Mounjaro, made by Eli Lilly. Each pre-filled KwikPen contains four weekly doses. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes over 72 weeks; participants on 15 mg lost around 20–21% of body weight on average, with some analyses reaching roughly 22.5%. Those are trial conditions, real-world results vary, and a prescriber will help you form realistic expectations based on your health picture, not headline figures.

A useful one-minute check: look up the GPhC register at pharmacyregulation.org/registers before you use any online pharmacy. If a pharmacy is not listed, it is not legally authorised to dispense prescription medicines in the UK. That takes about 40 seconds and tells you a lot.

The eligibility factors that shape a prescriber's decision on tirzepatide

The licensed private criteria are straightforward on paper: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, raised cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance typically applies thresholds 2.5 kg/m² lower. But BMI alone is never the whole story.

A prescriber also considers your medical history, current medicines, and whether tirzepatide is appropriate alongside your other health conditions. Certain situations require extra care or make tirzepatide unsuitable: a history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and some gastrointestinal conditions are among them. Pregnancy, breastfeeding, trying to conceive, and being under 18 are all contraindications under the UK licence. The consultation is where these factors are weighed properly, not a checklist you run through yourself.

NICE recommended tirzepatide (TA1026, December 2024, updated September 2025) for NHS use in adults with a BMI of 35 or above plus at least one weight-related comorbidity. NHS access is being phased in gradually; weight-loss injections on the NHS currently reach only a narrow band of patients. Private prescription through a regulated pharmacy means no referral and no waiting list, subject to clinical suitability. You can read more about the full range of options on the treatment overview page.

Side effects: the pattern most people experience on tirzepatide

The side-effect profile is dominated by gastrointestinal symptoms: nausea, constipation, diarrhoea, reflux, burping, and occasionally vomiting. These are most noticeable when starting treatment or after a dose increase, and they typically settle over days to a couple of weeks for most people. Fatigue, headache, dizziness, and injection-site reactions also occur. The NHS's tirzepatide medicines page sets out the full side-effect list clearly.

Two things worth knowing beyond the standard list. First, acute pancreatitis is a known but infrequent risk: if you develop severe, persistent stomach pain that spreads to your back, with or without vomiting, seek urgent medical help rather than waiting to see if it settles. Second, tirzepatide can reduce the absorption of oral contraceptives during the first four weeks of treatment and for four weeks after each dose increase; using an additional non-oral method during those windows is the current clinical recommendation. HRT users should discuss whether transdermal formats are preferable. Bring both topics up at consultation if they apply to you.

Tirzepatide's comparison against semaglutide is a common question. If you are weighing up the two medicines, you can explore what Wegovy achieves for weight loss and read about wegovie to understand semaglutide's evidence and how the two medicines differ in mechanism and trial results, which is useful context if you are still choosing between them.

What access through a regulated UK pharmacy looks like in practice

Tirzepatide is a prescription-only medicine. The only legal route to it in the UK is a prescription issued by a qualified prescriber following a clinical assessment. That assessment is not a formality, it is the step that establishes whether treatment is appropriate for you and safe to proceed with.

At nume, the process runs like this: you complete a free consultation, a GPhC-registered Independent Prescriber reads your answers the same day, and if treatment is clinically appropriate your prescription is issued and your order dispatched. Orders placed before 12pm on a working day are sent the same day; a DPD tracked delivery arrives the next working day, in plain packaging. Every repeat order goes through a fresh clinical review, there are no automatic renewals. Our about us page explains how the service is set up, and you can read about our clinical team's approach on the clinical team profile. If you have questions before starting, the FAQs are a practical first stop.

The cost of private treatment varies by dose and provider. One transparent price at nume covers consultation, prescription, treatment and free tracked delivery, no subscription, no hidden fees. If you want to understand what the market looks like before committing, the weight-loss injection cost page gives honest context on pricing. When you are ready, speak to our prescribers about whether tirzepatide is right for you.